Showing results (941-950 of 1,163) with videos related to

Sort By:
Pageof 117
European Journal of Heart Failure|October 1, 2025
Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registryWan Ting Tay, Tiew-Hwa Katherine Teng, Wouter Ouwerkerk, et al.
European Journal of Heart Failure|March 12, 2025
Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of CardiologyMaurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, et al.
Circulation|September 28, 2024
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart FailureMuthiah Vaduganathan, Brian L Claggett, Ian J Kulac, et al.
JAMA Cardiology|November 17, 2024
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionOrly Vardeny, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|February 5, 2026
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HFMisato Chimura, Alasdair D Henderson, Pardeep S Jhund, et al.
The Lancet. Diabetes & Endocrinology|June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
Journal of the American College of Cardiology|May 31, 2023
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection FractionMatteo Pagnesi, Marco Metra, Alain Cohen-Solal, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEFMingming Yang, Alasdair D Henderson, Inder S Anand, et al.
Pageof 117